Results of high dose 106-ruthenium irradiation of choroidal melanomas

Journal Article · Wed Oct 01 04:00:00 EDT 1986 · Int. J. Radiat. Oncol., Biol. Phys.; (United States)

DOI:https://doi.org/10.1016/0360-3016(86)90315-9· OSTI ID:6914317

Mueller, R P.B.; Busse, H; Poetter, R K; Kroll, P; Haverkamp, U

The favored treatment of intraocular melanomas in Germany is 106-ruthenium eye plaque therapy. The Departments of Radiation Therapy and Ophthalmology (University of Muenster) initiated a clinical study in 1981 to reveal the effect of high-dose beta irradiation (15.000 cGy to the apex of the tumor) regarding tumor regression, treatment related side effects, visual acuity, and survival. Sixty-seven patients have been treated since 1981. In 12 patients a second course of irradiation has been performed because of insufficient tumor regression or no change after the first plaque treatment. Sixty-five percent (44/67 pts.) were over 60 years of age. Twenty-four patients had a small tumor (up to 3 mm in height), 20 patients had a medium sized tumor (3.1-5 mm in height), and 22 patients had a large tumor (more than 5.1 mm in height). Fifty-one patients had a follow-up of at least 12 months. A total tumor regression was achieved in 34/51 patients (67%), partial tumor regression occurred in 13/51 patients (25%), and in 4/51 patients (8%) there was no change after the first course. After the second course of 106-ruthenium-irradiation 5 of the 12 patients showed total tumor regression, 3 had partial regression, and in 4 patients only an increase of the tumor echogenity could be assessed by ultrasonography, but no change in height. Visual acuity, which depends mostly on the localization of the tumor, was preserved at pretreatment levels in 72% of the patients. Two patients died with documented metastatic disease, one patient died of myocardial infarction. There was only one enucleation because of neovascular glaucoma.A

• Research Organization: Univ. of Muenster, West Germany
• OSTI ID: 6914317
• Journal Information: Int. J. Radiat. Oncol., Biol. Phys.; (United States), Journal Name: Int. J. Radiat. Oncol., Biol. Phys.; (United States) Journal Issue: 10 Vol. 10; ISSN IOBPD
• Country of Publication: United States
• Language: English

Related Subjects

550604 -- Medicine-- Unsealed Radionuclides in Therapy-- (1980-)
560161* -- Radionuclide Effects
Kinetics
& Toxicology-- Man
62 RADIOLOGY AND NUCLEAR MEDICINE
63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT.
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
BODY
BODY AREAS
DISEASES
EVEN-EVEN NUCLEI
EYES
FACE
HEAD
IMPLANTS
INTERMEDIATE MASS NUCLEI
ISOTOPE APPLICATIONS
ISOTOPES
MEDICINE
MELANOMAS
NEOPLASMS
NUCLEAR MEDICINE
NUCLEI
ORGANS
PATIENTS
RADIATION SOURCE IMPLANTS
RADIATION SOURCES
RADIOISOTOPES
RADIOLOGY
RADIOTHERAPY
RUTHENIUM 106
RUTHENIUM ISOTOPES
SENSE ORGANS
SIDE EFFECTS
SURVIVAL TIME
THERAPY
VISION
YEARS LIVING RADIOISOTOPES